Statement of Principles concerning ingrown nail (Reasonable Hypothesis) (No. 72 of 2024)

The instrument rests on a small set of core legal and medical concepts, defined or applied as the basis for decision making. These concepts and their mechanical effects are:

• Defined medical meaning of "ingrown nail": The instrument replaces purely code‑based description by a clinical definition , "the nail plate penetrates the soft tissue of the adjacent nail fold resulting in inflammation and pain" , and explicitly includes retronychia (subsection 7(2)). The instrument also notes the ICD‑10‑AM code L60.0 but makes clear that the textual definition controls for its purposes (subsections 7(2) and 7(3)).

• Death linked to the condition: "Death from ingrown nail" covers death from a terminal event or condition that the ingrown nail contributed to, and "terminal event" is exemplified in the Schedule (subsection 7(5); Schedule 1). Those exemplars include pneumonia, respiratory failure, cardiac arrest, circulatory failure, and cessation of brain function (Schedule 1).

• Reasonable hypothesis threshold: The instrument sets a statutory evidentiary threshold of a "reasonable hypothesis" connecting the condition or death to relevant service. It does not define the term in this instrument but operationalises it by requiring at least one enumerated factor to exist before the reasonable hypothesis is deemed to be raised (Factors that must exist, section 9).

• Enumerated factors and temporal windows: Section 9 lists the factors, each with temporal qualifications for when they must have been present in relation to clinical onset or clinical worsening. The factors include anatomical deformity, recent injury, specific medications, personal hygiene or grooming practices, footwear compression exposures, hyperhidrosis, diabetes mellitus, fungal infection, and inability to obtain appropriate clinical management. Temporal windows are precise, for example: injury within 6 months before clinical onset or worsening; certain medications within 6 months; excessive toenail trimming within 14 days; footwear compression for at least 8 hours within the prior 4 weeks; hyperhidrosis within 7 days; fungal infection within 1 year (section 9).

• Relationship to "relevant service": The instrument does not accept the mere presence of a listed factor; it requires that the existence of any factor be related to the person's relevant service as defined in the Schedule (section 10(1) and Schedule 1). "Relevant service" is a statutory list including operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1).

• Interaction with other Statements of Principles: If a listed factor refers to an injury or disease for which another Statement of Principles exists, that other Statement applies according to its own terms "as in force from time to time" (section 11). This creates a dynamic, cross‑referencing schema for multi‑factor causation.

These concepts dictate the data points that must be proved or established in a claim: clinical diagnosis matching the instrument's definition; presence of at least one enumerated factor within the stated temporal window; evidence linking that factor to the veteran's relevant service; and, where applicable, reliance on other Statements of Principles for linked conditions. The instrument therefore translates medical attributes and service history into a statutory causation gate for claims under the VEA and MRCA (sections 5, 7, 9, 10, 11).

The instrument affects claimants and decision makers operating under two statutory claim routes: claims to which section 120A of the Veterans' Entitlements Act 1986 applies and claims to which section 338 of the Military Rehabilitation and Compensation Act 2004 applies (Application, section 5). Practically, the instrument will affect the following groups.

• Veterans, members of Peacekeeping Forces, and members of the Forces covered by the VEA or MRCA who lodge claims that allege ingrown nail or death from ingrown nail as connected to their relevant service. The definition of "relevant service" in the Schedule lists the categories of service that can give rise to claims under this instrument, including operational service, peacekeeping, hazardous service, British nuclear test defence service, and warlike or non‑warlike service under the MRCA (Schedule 1). Only persons whose service fits those statutory categories are within the instrument's scope.

• Medical practitioners providing opinions for claims. The instrument sets out the clinical definition of ingrown nail and specific temporally bounded factors that will suffice to raise the required causal hypothesis (subsection 7(2) and section 9). Practitioners preparing medical reports will need to record timing and clinical data that align with those precise factor windows, and demonstrate any link between the factor and the veteran's relevant service.

• Decision makers and administrators who apply Statements of Principles. The Repatriation Medical Authority made the instrument under the statutory power in subsection 196B(2) of the VEA (Authority, section 3). Relevant administrative decision makers will use the instrument as the evidentiary standard to determine whether the reasonable hypothesis of service connection is met for claims under the cited statutory provisions (sections 5 and 9).

• Departments or agencies responsible for claims adjudication and for obtaining medical records and service records. The instrument focuses adjudication on a small set of discrete factors and temporal windows, which will shape record requests and evidentiary evaluation.

• Parties linked by cross‑referencing Statements of Principles. Section 11 makes other Statements of Principles relevant where a factor refers to an injury or disease already covered by another Statement. This means that claimants with comorbidities or related injuries must consider multiple Statements when assembling evidence.

Who does not automatically gain entitlements from this instrument: the instrument itself does not create an entitlement; it provides a causation test for claims under the specified statutes. It does not extend to persons whose service is outside the statutory "relevant service" categories in the Schedule. It does not provide prescriptive clinical management or funding rules; it only informs the causation assessment for VEA and MRCA claims (sections 5, 7, Schedule 1).

This instrument sets out no general duties or rights in the sense of obligations or privileges enforceable directly by the instrument itself. Instead, it functions as an evidentiary instrument that imposes an operational duty on decision makers and an evidentiary requirement on claimants to show, for causation purposes, that at least one listed factor existed and was related to the person's relevant service.

• Duty to apply the Statement in claims under specified statutory provisions: Where a claim falls under section 120A of the VEA or section 338 of the MRCA, the Statement governs the raising of a reasonable hypothesis connecting ingrown nail or death from ingrown nail with service (Application, section 5). Decision makers adjudicating such claims must assess whether the factors in section 9 are present, and whether they are related to relevant service, before finding that the reasonable hypothesis is raised (sections 9 and 10(1)).

• Duty to treat the textual definition as controlling: Although an ICD‑10‑AM code is cited, the instrument directs that ingrown nail has the meaning provided in subsection 7(2). Medical opinions and decision makers must therefore align their clinical assessments with that definition rather than relying solely on the code (subsections 7(1)-(3)).

• Requirement to demonstrate temporal relationship: The instrument establishes precise timing windows for each factor (section 9). For example, an injury to the nail or nail bed must have occurred within six months before clinical onset or clinical worsening; excessive trimming must have occurred within 14 days; footwear compression exposures must be at least eight hours within the four weeks before onset or worsening; hyperhidrosis within seven days; fungal infection within one year. Parties must address these temporal thresholds in evidence.

• Right to have other Statements of Principles applied where relevant: Section 11 provides that where a factor refers to an injury or disease already covered by another Statement, the factors in that Statement apply "in accordance with the terms of that Statement as in force from time to time". That creates a procedural right for claimants to rely on linked Statements, but also a duty on decision makers to apply those Statements and any updates to them when assessing the factor.

• Clinical worsening nuance and burden: Section 10(2) clarifies that the "clinical worsening" aspect of section 9 applies only to material contribution to, or aggravation of, ingrown nail where the person's ingrown nail was suffered or contracted before or during, but did not arise out of, their relevant service. That introduces a specific legal distinction: clinical worsening is relevant to aggravation of pre‑existing conditions that have not been caused by service. Parties must therefore present evidence about whether the condition "arose out of" service or was merely suffered during service, and if suffered during service but not caused by it, whether service materially aggravated it.

• No penalties or enforcement mechanisms in the instrument: The Statement does not itself create offences, regulatory penalties, or administrative sanctions. Its role is to inform the causation assessment under the VEA and MRCA; any enforcement or benefit outcomes will flow from administrative decisions under those Acts (Authority and Application, sections 3 and 5).

Collectively, these provisions put a practical evidentiary duty on claimants to gather time‑stamped medical and service records, and on medical advisers and decision makers to align their causal reasoning with the enumerated factors and temporal windows. They also create a procedural entitlement to have other relevant Statements of Principles applied where factors cross‑refer to separate conditions (section 11).

The instrument does not prescribe criminal penalties, civil sanctions, or explicit enforcement mechanisms. It is a Statement of Principles made under subsection 196B(2) of the Veterans' Entitlements Act 1986 and functions as an evidentiary standard for determining whether a reasonable hypothesis has been raised connecting ingrown nail or death from ingrown nail with relevant service (Authority, section 3; Factors that must exist, section 9). There are therefore no fines, imprisonment terms, or administrative penalties contained within this instrument itself.

Enforcement in the sense of decisions about entitlements will occur under the VEA and MRCA frameworks. The instrument applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (Application, section 5). Those statutory provisions and their implementing administrative procedures determine benefit outcomes, review rights, and appeal routes. The Statement merely informs the causal assessment that decision makers will use when applying those statutory schemes. The instrument does not describe the decision‑making process, review rights, or remedies; those remain in the parent Acts and associated procedural instruments.

Because the Statement sets an evidentiary threshold rather than a sanction, the "enforcement" consequence is practical and binary in claims processing: if the decision maker accepts that the requisite factor(s) exist, and those factors are related to relevant service, then the reasonable hypothesis is raised; if not, the reasonable hypothesis is not raised. The instrument leaves to the VEA and MRCA regimes the consequences of that determination for entitlement to compensation, rehabilitation, or other benefits. Section 11's cross‑reference to other Statements of Principles also has an enforcement implication: decision makers must apply those Statements where a factor refers to another covered injury or disease, and those Statements may in turn affect entitlement outcomes.

Finally, because the Statement defines particular temporal and clinical thresholds, failure by a claimant to provide evidence that meets those thresholds is likely to result in a negative causation finding. That is not a penalty directly imposed by the Statement, but a predictable result when it is applied within the statutory claims processes. The instrument contains no clause conferring investigative or compliance powers on any agency beyond what is in the parent Acts, and it contains no provisions about sanctions for false statements, record‑keeping obligations, or similar enforcement measures.

The instrument is expressly made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (Authority, section 3) and applies to claims for which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies (Application, section 5). Its legal effect is therefore primarily within the statutory schemes of the VEA and the MRCA. The instrument interacts with other laws in the following ways, as described in its text.

• Statutory anchoring and application: The Statement is an instrument under the VEA power and thereby functions as a component of the statutory causation assessment under the VEA and the MRCA where the specified claim sections apply (sections 3 and 5). The content of the Statement is to be used by decision makers as authoritative guidance in raising a "reasonable hypothesis" of service connection.

• Cross‑reference to other Statements of Principles: Section 11 provides a direct interaction rule. If a factor in this Statement refers to an injury or disease already covered by another Statement of Principles made under subsection 196B(2) of the VEA, then "the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time" (section 11). This creates an operational linkage between Statements and allows for dynamic application of other Statements when evaluating a factor in this instrument. As a result, changes to linked Statements may affect how a factor in this Statement is applied.

• Interaction with classification systems: The instrument references ICD‑10‑AM code L60.0 but states that, in applying the Statement, the meaning of ingrown nail is the textual definition supplied in subsection 7(2) (subsections 7(2)-(3)). Thus, while clinical classification codes are acknowledged, the instrument makes the text controlling for legal purposes. Decision makers must therefore reconcile clinical coding with the instrument's textual definition when applying the law.

• Relationship to service categories in Schedule 1: The Schedule defines "relevant service" by reference to specific categories under the VEA and MRCA. That links the instrument to the statutory definitions of service types used elsewhere in the VEA and MRCA regimes and ensures that only those service categories attract the instrument's causation mechanics (Schedule 1).

• No displacement of other legal regimes: The instrument does not state that it overrides other laws beyond its function within the VEA/MRCA causal assessment. It does not purport to alter criminal law, general tort law, workers' compensation, or private medical obligations. Its reach is limited to the statutory claims and the causation question under those Acts (Application, section 5).

• Dynamic application: Because section 11 expressly ties applicability of other Statements of Principles "as in force from time to time", the instrument incorporates future amendments to related Statements without need for amendment to this document. That introduces an ongoing interaction where updates in other Statements will automatically affect how linked factors operate when adjudicating ingrown nail claims.

In short, the instrument is not freestanding; it is a component in the statutory machinery of veteran entitlements and compensation. Its legal effect is primarily to standardise the causation assessment for ingrown nail and linked deaths for claims falling under specified provisions in the VEA and MRCA. It cross‑links to other Statements of Principles and to the parent Acts but does not itself create standalone rights or offences outside that statutory matrix.

The instrument records a limited internal amendment history within its own text. It is a new Statement of Principles designated No. 72 of 2024, dated 20 August 2024, and it commences on 24 September 2024 (Authority and Commencement, sections 3 and 2). The sole repeal action contained in the instrument is the repeal of the Statement of Principles concerning ingrowing nail No. 106 of 2015 (Federal Register of Legislation No. F2015L01326), which was made under subsection 196B(2) of the VEA (Repeal, section 4). The instrument does not list any other past amendments or a history of incremental changes; it effects a replacement of the 2015 Statement by this 2024 Statement.

The instrument also contains an express mechanism that affects how subsequent updates to other legal instruments will interact with it. Section 11 binds this Statement to "other Statement[s] of Principles ... as in force from time to time" when a factor in this instrument refers to an injury or disease covered by another Statement. That language imports a form of dynamic amendment interaction: subsequent amendments to other Statements will automatically be applied when assessing factors that cross‑refer. The present instrument does not itself provide a template for its own future amendment process beyond that normal course under the power in subsection 196B(2) of the VEA.

Other historical metadata in the instrument is limited to the date and the authority under which it is made. The Schedule and the body text do not describe consultations, the evidentiary basis in detail beyond the assertion of "sound medical‑scientific evidence" (Basis for determining the factors, section 8), or a list of drafts. The instrument therefore presents as a discrete, replacement Statement with the following explicit amendment history: repeal of the prior 2015 Statement and establishment of this 2024 Statement, commencing on the stated date (sections 4 and 2). Any further amendments will be implemented by the Repatriation Medical Authority under the same statutory power, and changes to other Statements will affect this instrument to the extent that section 11 cross‑references them "as in force from time to time".

The instrument itself contains no record of litigation and names no cases. There are no judicial determinations cited or reproduced in the text. The Statement presents the Repatriation Medical Authority's view that there is sound medical‑scientific evidence linking ingrown nail and death from ingrown nail to relevant service (Basis for determining the factors, section 8), but the instrument does not reference court decisions or administrative appeals that have tested that view.

The absence of litigation history in the instrument has several practical implications for advisers and decision makers. First, because the instrument sets out discrete factors and temporal thresholds but does not cite case law, interpretation disputes may arise and could be litigated in the future. For example, questions could concern what constitutes sufficient evidence that a listed factor "was related to the relevant service" (Relationship to service, section 10(1)), how to determine clinical onset or clinical worsening for temporal tests (section 9), or how to apply the cross‑reference in section 11 to Statements "as in force from time to time". None of these interpretive issues are resolved within the instrument itself.

Second, a lack of prior adjudication means administrative decision makers will need to rely on statutory text and the instrument's plain language for first‑instance reasoning, which increases the operational significance of precise phraseology in the instrument. The specific temporal windows and categorical inclusions (for example, footwear compression defined by minimum hours and lookback windows) will be focal points in any review or appeal that challenges an adverse decision.

Third, because the instrument replaces an earlier 2015 Statement (Repeal, section 4), there may be an existing administrative record of prior adjudications under the repealed instrument. The present instrument does not record whether or how precedent under the 2015 Statement should be treated. Parties relying on decisions made under the old Statement will need to address whether those decisions remain persuasive or binding under current procedural rules for review, but the instrument itself is silent on retrospective application, leaving that issue to the parent Acts and to administrative practice.

Finally, because the instrument cross‑references other Statements of Principles "as in force from time to time" (section 11), future litigation may involve multiple Statements and questions about which version of a linked Statement applies to decisions made on particular dates. That dynamic can give rise to procedural complexity that could be litigated. The instrument does not catalogue any such litigation history; practitioners should therefore expect interpretive and evidentiary disputes to be resolved initially through administrative processes and possibly, if contested, through judicial review or merits review channels established by the VEA and MRCA regimes.

Practical pitfalls and non‑obvious features of the instrument that commonly affect claims are set out below, with reference to the controlling text.

• Textual, not code‑only, definition: Although subsection 7(3) references ICD‑10‑AM code L60.0, subsection 7(2) supplies the operative definition of ingrown nail for legal purposes. Practitioners should not assume that an ICD‑10 code alone satisfies the instrument; the clinical features must match the textual definition, including penetration of the soft tissue and inflammation/pain. Failing to align the diagnosis to subsection 7(2) can lead to a missing link in causation.

• Strict and varied temporal windows: Each enumerated factor has a precise temporal lookback tied to clinical onset or clinical worsening (section 9). For instance, medications are limited to "within the 6 months before clinical onset or clinical worsening", excessive trimming has a 14‑day window, footwear compression requires at least 8 hours of exposure within the prior 4 weeks, hyperhidrosis and inability to wash feet have 7‑day windows, and fungal infection has a 1‑year window. Evidence that does not meet those temporal thresholds may be excluded as insufficient to raise the reasonable hypothesis.

• "Clinical onset" and "clinical worsening" distinctions: The instrument uses both terms but does not define them precisely. Clinical worsening is only applicable where the condition was suffered or contracted before or during, but did not arise out of, relevant service (section 10(2)). That means claimants whose condition arose out of service will not rely on the clinical worsening limb, while those with pre‑existing conditions suffered during service but not caused by it must show material contribution or aggravation. The absence of precise definitions for onset and worsening increases the importance of contemporaneous medical records.

• Requirement to link a factor to relevant service: The instrument requires that any factor relied on be "related to the relevant service rendered by the person" (section 10(1)). This is not established simply by proving the factor existed; claimants must show how that factor was connected to the service event or period. That link is a separate element of proof.

• Cross‑referenced Statements dynamic: Section 11 makes application of other Statements subject to their terms "as in force from time to time". That creates a moving target for interpretation. If a factor refers to another injury or disease, decision makers must look to the current version of the linked Statement at the time of assessment, which may have changed since the event. Practitioners must track relevant Statements and their amendments.

• Medications list specificity: The drugs listed in section 9 include oral retinoids, indinavir, epidermal growth factor inhibitors, and cyclosporine. If a claimant relies on medication, the medical record must show exposure to these specific agents within six months. Drugs outside this list, or uncertainty about prescription dates, will weaken the causal case.

• Footwear exposure threshold: The footwear factor requires compression or pressure "for at least 8 hours within the 4 weeks before clinical onset or clinical worsening" (section 9). Casual, singular short exposures may not meet this threshold. Evidence must address both the duration and the timing.

• "Inability to obtain appropriate clinical management": The instrument lists this as a factor without defining what constitutes "appropriate clinical management" or the reasons for inability. Claimants asserting this factor must provide explanatory evidence showing both the lack of access and a causal link to subsequent clinical worsening within the relevant timeframe (section 9). The absence of a definition makes evidentiary proof context‑dependent.

• Death causation requires contribution to a terminal event: The instrument allows "death from ingrown nail" only where the ingrown nail contributed to a terminal event or condition as those are exemplified in the Schedule (subsection 7(5); Schedule 1). Claimants must show causal contribution to one of the listed events or an equivalent terminal event; mere presence of an ingrown nail at time of death is not sufficient.

• Repeal of the prior Statement: Because the 2015 Statement is repealed (section 4), prior claims adjudicated under the older instrument may not be authoritative for decisions made under this instrument. Practitioners should check whether the timing of the claim aligns with the commencement date (24 September 2024) when deciding which Statement applies.

• No procedural or evidentiary guidance inside the instrument: The Statement sets causal factors but does not detail the evidentiary standard of proof beyond the "reasonable hypothesis" label, nor does it explain how to weigh conflicting medical evidence. That leaves interpretive weight to decision makers and their established procedures under the VEA and MRCA.

These "gotchas" arise from the instrument's reliance on precise temporal windows, textual definitions, cross‑referencing, and the requirement that factors be related to relevant service. In practice, claimants should ensure that medical records, service records, medication histories, and contemporaneous evidence address these specific elements.

Complying with this Statement of Principles means aligning medical, factual, and service evidence to the instrument's textual definitions, enumerated factors, and temporal windows so that a decision maker can conclude that a reasonable hypothesis has been raised linking ingrown nail or death from ingrown nail to relevant service (Application, section 5; Factors, section 9; Relationship to service, section 10). The following practical steps are aligned with the instrument's requirements.

• Confirm that the claim falls within the instrument's application: Verify that the claim is subject to section 120A of the VEA or section 338 of the MRCA (Application, section 5). If it is not, this Statement will not govern the causation assessment.

• Establish the medical diagnosis against the instrument's textual definition: Ensure clinical notes explicitly record that the nail plate penetrated the soft tissue of the adjacent nail fold producing inflammation and pain, and whether retronychia is present if relevant (subsection 7(2)). Do not rely solely on ICD‑10‑AM coding; the instrument directs that the textual definition controls (subsections 7(2)-(3)).

• Identify and document at least one enumerated factor with precise timing: Section 9 lists the alternative factors and their temporal windows. For each relied upon factor, provide contemporaneous medical notes, treatment records, or other evidence showing:

  • For deformity, a documented acquired deformity of the affected digit that caused the nail to be pushed into adjacent soft tissue at time of clinical onset (section 9(1)).
  • For injury, records showing an injury to the nail or nail bed within six months before clinical onset or worsening (section 9(2)).
  • For medication exposures, prescription or dispensing records showing use of one of the listed agents (oral retinoids, indinavir, epidermal growth factor inhibitors, cyclosporine) within six months (section 9(3)).
  • For grooming practices, statements, podiatry notes or witness evidence of excessive trimming or rounding of nail corners within 14 days before onset or worsening (section 9(4)).
  • For footwear, evidence that the footwear caused compression or pressure for at least eight hours within the four weeks before onset or worsening, for example logbooks, duty records, or contemporaneous statements (section 9(5)).
  • For hyperhidrosis or inability to wash feet/socks, clinical notes or supporting testimony within seven days before onset or worsening (sections 9(6) and 9(7)).
  • For diabetes mellitus, medical records indicating diagnosis at the time of onset or worsening (section 9(8)).
  • For fungal infection, laboratory or clinical diagnosis within one year before onset or worsening (section 9(9)).
  • For inability to obtain appropriate clinical management, documentation showing attempts to obtain care and reasons for failure, and their timing relative to clinical worsening (section 9(10)).

• Demonstrate the relationship to relevant service: Section 10(1) requires that any factor must be related to the person's relevant service. Provide service records, duty rosters, postings, or contemporaneous military medical records that show how the factor arose from or was connected to the service identified in the Schedule's "relevant service" categories.

• Address the "clinical worsening" nuance where relevant: If relying on clinical worsening to show material contribution or aggravation, show that the ingrown nail was suffered or contracted before or during, but did not arise out of, the relevant service as required by section 10(2). In that case, present comparative clinical assessments showing pre‑service baseline, in‑service status, and post‑service worsening.

• Use cross‑References where appropriate: If a factor refers to an injury or disease covered by another Statement of Principles, identify the relevant Statement and apply its terms as in force at the time of assessment (section 11). Obtain and rely on medical evidence in line with that other Statement as required.

• Prepare expert medical opinion aligned to the instrument: Medical experts providing causation opinions should explicitly address the factors listed in section 9, the relevant lookback windows, the textual definition of ingrown nail, and the link to relevant service under section 10. Opinions should state whether, on the basis of the available evidence, the listed factor existed and was related to the claimed service.

• Maintain contemporaneous evidence of onset and exposures: Since the instrument hinges on precise temporal windows, contemporaneous records (clinic notes, prescriptions, service records, footwear issue logs, podiatry reports) will be decisive. After‑the‑fact recollections without supporting records are less persuasive given the specific timing requirements.

• Track amendments to linked Statements: Because section 11 imports other Statements "as in force from time to time", keep updated copies of any Statements of Principles referenced by a factor, and apply the current version when preparing or defending claims.

• Understand limitations: The Statement does not itself create entitlements. It informs the causation assessment under the VEA and MRCA. Therefore, ensure that all procedural requirements of the parent Acts are followed, including lodgement procedures, time limits, and review rights which are not contained in this instrument.

Following these steps aligns documentary and expert evidence with the instrument's textual requirements and assists decision makers in determining whether the "reasonable hypothesis" threshold is met for ingrown nail or death from ingrown nail in the context of VEA and MRCA claims.